Sysmex Nederland
Menu

OSNA in breast cancer

Axillary management and the relevance of sentinel lymph node biopsy (SLNB) have undergone major changes in the last years. Clinical trials, which have investigated less invasive treatment approaches as a replacement of axillary surgery, indicate that axillary dissection can be omitted in patients with limited metastatic involvement. Consequently, treatment decisions and nodal staging more often have to be based solely on the diagnostic information derived from the sentinel lymph node (SLN).

More than 100 publications provide evidence on the clinical utility of using OSNA and the CK19 copy number for SLN assessment. They show that CK19 provides predictive and prognostic information beyond conventional pathology assessment. This helps clinicians better select who can be safely spared an ALND, allows more personalised treatment decisions and improves patients’ quality of life.

Description

Do you get all this from your current sentinel lymph node analysis? CK19 mRNA expression level:

Excellent diagnostic information

  • More accurate determination of the metastatic burden by analysis of the entire lymph node
  • Standardised, objective assessment of lymph node status

Confidence

  • Fast availability of results for optimal decision making on the right surgical/ non-surgical approach
  • Confident staging as reliable basis for therapy choice

Patient quality of life

  • Permits earlier start of further therapy measures
  • Reduced waiting time and less patient stress

 

Contact
You have a question and would like to get in touch with our experts? We look forward to receiving your enquiry.

Sysmex Nederland B.V.

Ecustraat 11

4879 NP Etten-Leur

The Netherlands

+31 (0)76 508 6000

+31 (0)76 508 6086

Sysmex Belgium N.V.

Chaussée de Bruxelles 135A

1310 La Hulpe

Belgium

+32 (0)2 769 7474

+32 (0)2 7697499

Explore more

Copyright © Sysmex Europe SE. All rights reserved.